Eli Lilly price target raised to $1,101 from $1,001 at BMO Capital

BMO Capital raised the firm’s price target on Eli Lilly to $1,101 from $1,001 and keeps an Outperform rating on the shares. The firm cites the company’s Q2 earnings beat and the “exceptional execution” on the largest BioPharma manufacturing expansion since the pandemic, the analyst tells investors in a research note. Commercial excellence and nimbleness in the U.S. market is becoing the expectations from Lilly after its two healthy guidance raises in a row, BMO added.